Cipla Technologies, Pulmatrix agree for development and commercialization of Pulmazole
Cipla shall now have exclusive rights for the development and commercialisation of Pulmazole in all countries except the United States of America
Cipla shall now have exclusive rights for the development and commercialisation of Pulmazole in all countries except the United States of America
Arco Lab now holds a 50% stake in Neviton
Lays Foundation Stone of 6 new facilities at AIIMS Bhopal and inaugurates a slew of facilities in Madhya Pradesh
The acquisition of the shares of Adita result in growth opportunities in line with strategic objectives of the company
Collaboration provides AstraZeneca with exclusive rights to Omniose’s proprietary bioconjugation platform to explore potential vaccines for a broad range of bacterial pathogens
The deal includes upfront payments, milestone payments and ongoing royalties
Comprehensive clinical development programs being initiated for each investigational candidate
Base4's drug discovery platform allows its collaborators to evaluate billions of novel small molecules to identify and progress RNA-modulators for important diseases
Subscribe To Our Newsletter & Stay Updated